Process for making T cell hybridomas

DETAILED DESCRIPTION We claim: 1.
A process for making a T cell hybridoma comprising: a.
Fusing an azaserine-hypoxanthine sensitive human T leukemia cell line with normal human T cells; and b.
culturing the product of step a.
in a selective azaserine-hypoxanthine medium, wherein said human T leukemia cell line is a derived from the Jurkat human T cell line.
2.
The process of claim 1 wherein the T cell hybridoma is a human T cell hybridoma, the T leukemia cell line is a human T leukemia line and the normal T cells are normal human T cells.
3.
The process of claim 2 wherein the normal human T cells have been treated with an inducer that induces production of an immunoregulatory agent or a soluble mediator of cellular immunity.
4.
The process of claim 3 wherein the inducer induces production of IL-2.
5.
The process of claim 4 wherein the azaserine-hypoxanthine sensitive human T leukemia line has the identifying characteristics of the human T leukemia cell line ATCC number CRL 8169.
6.
The process of claim 4 wherein the azaserine-hypoxanthine sensitive human T leukemia line is the J3R7 cell line.
7.
The process of claim 1 wherein polyethylene glycol is used as a fusogen in step (a).
8.
The process of claim 2 wherein the concentration of azaserine in the medium is about 1 to 20 .
mu.
g/ml and the concentration of hypoxanthine in the medium is about 100 .
mu.
M.
9.
The process of claim 8 wherein the azaserine-hypoxanthine sensitive T leukemia cell line has the identifying characteristics of ATCC number CRL 8169.
10.
The process of claim 8 wherein the azaserine-hypoxanthine sensitive T leukemia cells are cells of the Jurkat cell line.
11.
An azaserine-hypoxanthine sensitive mutant of the Jurkat human T leukemia cell line and progeny thereof.
12.
A human T leukemia cell line having all the identifying characteristics of ATCC number CRL 8169 and progeny thereof.
13.
Jurkat human T leukemia cell line J3R7 and progeny thereof.
14.
A method for the production of IL-2 comprising: c.
culturing a hybridoma produced by the fusion of an azaserine-hypoxanthine sensitive human T cell leukemia cell line and a normal human T cell, wherein said human T leukemia cell line is derived from the Jurkat human T cell line, and wherein the cloning is carried out in the presence of an inducer which induces IL-2 production; d